Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dorzagliatin + GLP-1 receptor agonist
- Development stage
- Preclinical
- Lead developer
- Hua Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dorzagliatin + GLP-1 receptor agonist is a combination therapy in development by Hua Medicine for the treatment of Type 2 Diabetes and Obesity. The combination utilizes dorzagliatin (HMS5552), a first-in-class, dual-acting glucokinase activator (GKA) that restores the function of glucokinase, the body's primary glucose sensor, in the pancreas, liver, and intestines. By pairing dorzagliatin with a GLP-1 receptor agonist, the treatment aims to achieve synergistic effects on insulin secretion and glucose homeostasis. Preclinical and clinical research suggests that dorzagliatin can enhance endogenous GLP-1 secretion, and the combination therapy is designed to further improve beta-cell function and glucose sensitivity, potentially offering superior post-meal glycemic control and weight management compared to monotherapy. The program is currently listed as a small molecule combination in the developer's pipeline.
- Other names
- Dorzagliatin + GLP-1 RADorzagliatin + GLP1RA
02
Targets
GCK (Glucokinase)GLP1R (GLP-1R)
Beyond the preview
Go deeper on dorzagliatin + GLP-1 receptor agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dorzagliatin + GLP-1 receptor agonist.